Genovis Q4 2022: Initial Take - Redeye

Redeye provides its initial take on Genovis’ Q4 2022 report, which came in substantially below our expectations on the EBIT level due to a SEK-9m one-off item. The one-off aside, the report was just short of our estimates, we view it as a minor setback. We will return with a research update shortly, where we give an elaborate take on the report and the sublicensing of Xork to Astellas Pharma.

Länk till analysen i sin helhet: https://www.redeye.se/research/877860/genovis-q4-2022-initial-take?utm_source=finwire&utm_medium=RSS